Weinberg Uri's Form 4 filing
NovoCure Ltd (NVCR) · filed Mar 5, 2026
- Accession no.
- 0001811030-26-000003
- Filed
- Mar 5, 2026
- Trade date
- Mar 3-4, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $85.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Weinberg UriCIK 0001811030 | Officer (Chf Medical and Innovation Ofr) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | Ordinary Shares | AGrant or awardAcquired | +50,125 | $0.00 | $0 | 273,602 | Direct | |
| Mar 4, 2026 | Ordinary Shares | SSaleDisposed | −6,412 | $13.31F3 | −$85,343.72 | 267,190 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | Ordinary Shares | AGrant or awardAcquired | +73,340 | $0.00 | $0 | 73,340 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.
Referenced by the price of 1 transaction in Table I.